Faculty Directory
Professors |
Associate Professors |
Assistant Professors |
Part-Time Associate Professors |
Part-Time Assistant Professors |
Associate Members |
NOTE: All phone and fax numbers are in the 514 area code unless otherwise indicated.
Professors
Name and email |
Phone |
Fax |
---|---|---|
M. Auger; M.D.,C.M. (McG.), F.R.C.P.(C)Email: manon.auger [at] mcgill.ca (Dr. Manon Auger) ProfileAfter obtaining her MD degree at McGill University, Dr. Auger completed her residency training in Anatomical Pathology at the University of Toronto, followed by a Cytopathology Fellowship at the University of Texas M.D. Anderson Cancer Center in Houston. Her interests include all aspects of cytopathology and she is passionate about teaching. Special Interests and Research Areas
Selected PublicationsEvidence-based diagnostic accuracy measurement in urine cytology using likelihood ratios. Myles N, Auger M, Kanber Y, Caglar D, Kassouf W, Brimo F J Am Soc Cytopathol 2021;10:71-78. Immunocytochemistry for diagnostic cytopathology—A practical guide. Kanber Y, Pusztaszeri M, Auger M. Cytopathology 2021; 32:562-587. Breast implant-associated anaplastic large cell lymphoma and effusions: A review with emphasis on the rôle of cytopathology. Julien LA, Michel RP, Auger M. Cancer (Cancer Cytopathol) 2020; 128:440-451 (doi: 10.1002/cncy.22233). A practical guide for ancillary studies in pulmonary cytologic specimens. Auger M, Brimo F, Kanber Y, Fiset PO, Camilleri-Broet S Cancer Cytopathology 2018;126:599-614 (DOI: 10.1002/cncy.22028)
|
934-1934 ex. 38772 |
934-8296 |
M.N. Burnier Jr.; M.D., Ph.D. (Brazil)Email: miguel.burnier [at] mcgill.ca (Dr. Miguel Burnier) ProfileDr. Miguel Burnier was the Chairman of the Department of Ophthalmology, McGill University, from 1993 to 2008. He is a Full Professor of Ophthalmology, Pathology, Medicine and Oncology at McGill and he was also the Thomas O. Hecht Family Chair in Ophthalmology (1996-2012). This is the first and the only endowment Chair of the Department of Ophthalmology. It was awarded to Dr. Burnier upon his arrival as Professor and Chair of the Department of Ophthalmology. Dr. Burnier is currently the General Director of Clinical Research & Training of the McGill University Health Centre Research Institute. Recent PublicationsA cystic epithelial downgrowth mimics an intraocular tumour following penetrating eye trauma. |
934-1934 ex. 38773 | 398-5728 |
A. Ferenczy; B.A., B.Sc., M.D. (Montr.)Email: alex.ferenczy [at] mcgill.ca (Dr. Alex Ferenczy) |
340-7526 | 340-7542 |
R. Fraser; B.Sc., M.D., C.M. (McG.), M.Sc.(Glas.) F.R.C.P.(C)Email: richard.fraser [at] mcgill.ca (Dr. Richard Fraser) |
934-1934 ex. 43858 |
934-8296 |
Z-H. Gao, M.D., Ph.D., F.R.C.P.(C) (adjunct)Email: zuhua.gao [at] ubc.ca (Dr. Zu-hua Gao) ProfileDr. Zu-hua Gao obtained his Medical degree from Qingdao Medical College, Master degree from Harbin Medical University, and PhD degree from Peking Union Medical College. Dr. Gao received his post-doctoral fellowship training at the Johns Hopkins Hospital, pathology residency training at Dalhousie University, and subspecialty pathology fellowship at the University of Chicago. As a surgical pathologist, Dr. Gao’s clinical expertise is gastrointestinal and liver pathology. As an educator, Dr. Gao teaches undergraduate medical students pathology courses, supervises graduate students, residents, and fellows. Dr. Gao has written three textbooks: the Clinical Skills Review for medical students (3 editions), the Pathology Review and Practice Guide book for pathology residents (2 editions, translated into 4 languages) and Gross Morphology of Common Diseases. As a research scientist, Dr. Gao published 168 peer reviewed articles, over 70 abstracts and meeting presentations, and 25 invited speeches at national and international venues. Dr. Gao received many awards including the Junior Scientist Award at CAP-ACP, the Dalhousie Medical Foundation award, the McGill University Health Center Foundation award, etc. As an administrator, Dr. Gao had been the Division Head of Anatomical Pathology and Cytopathology at the University of Calgary and Calgary Laboratory Services between 2007-2011. Since 2012, Dr. Gao has been the Chair and Chief of the Department of Pathology at McGill University. Since 2019, Dr. Gao has been the President of Canadian Chairs of Pathology and Laboratory Medicine. In 2017, Dr. Gao became a Fellow of the Royal Society of Medicine (London UK). In 2019, Dr. Gao became a Fellow of the Canadian Academy of Health Sciences. Selected PublicationsSinusoidal endotheliitis as a histological parameter for diagnosing acute liver allograft rejection Role of CCN5 (WNT1 inducible signaling pathway protein 2) in pancreatic islets Weighted gene co-expression network analysis of colorectal cancer liver metastasis genome sequencing data and screening of anti-metastasis drugs |
(604) 822-7102 | |
D. Haegert;M.D. (Br.Col.), F.R.C.P.(C)Email: david.haegert [at] muhc.mcgill.ca (Dr. David Haegert) ProfileDr. David G. Haegert earned his undergraduate degree from the University of Victoria, British Columbia, Canada, and his medical degree from the University of British Columbia. He completed his internship at the Royal Victoria Hospital, Montreal, and his residency training in Anatomic Pathology in the McGill University teaching hospitals. He received post-doctoral training in Immunology at the University of Cambridge, Cambridge, England. Dr. Haegert is a Fellow of the Royal College of Physicians and Surgeons of Canada in Anatomic Pathology. Selected PublicationsNaive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. |
934-1934 ex. 38777 | 934-8296 |
I. Hüttner; M.D. (Budapest), Ph.D. (McGill) F.R.C.P. (C)Professor Emeritus (Retired) ProfileDr. Istvan Hüttner completed his MD degree with "Summa Cum Laude" at the Semmelweis Medical University, Budapest, Hungary in 1961. He started his career by teaching and pursuing research in vascular pathology in the 2nd Department of Pathology of the same University where he obtained his certificate in Anatomical Pathology and held the title of Assistant Professor. In 1967-68 he obtained a postdoctoral fellowship at the Faculte de Medicine de Paris, France, then in 1969-71 he was awarded a Canadian Arthritis and Rheumatism Society Fellowship at McGill University, Montreal, Canada. While holding this latter fellowship, he started his research that led to original discoveries on vascular endothelium and his prominence in the field of vascular cell biology. He obtained a post-doctoral PhD degree in 1973 at McGill University, certificates in Anatomical Pathology by the American Board of Pathology, the College des Medecins du Quebec and became Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) in 1975. He was appointed to Assistant Professor in 1973, Associate Professor in 1976 and promoted to Full Professor in 1981 at the Department of Pathology, McGill University. He spent a sabbatical year as Visiting Professor at the University of Geneva, Switzerland in 1983-84 where he was also recipient of the Zyma Award. Selected PublicationsGap junctions in arterial endothelium. |
769-8349 | |
R.P. Michel; B.Sc., M.D., C.M. (McG.), F.R.C.P.(C)Email: rene.michel [at] mcgill.ca (Dr. Rene P. Michel) ProfileEducation Selected PublicationsAcute respiratory distress syndrome: 30 years later. |
934-1934 ex. 38779 | 934-8296 |
A. Spatz; MSc., M.D. (Paris)Email: alan.spatz [at] mcgill.ca (Dr. Alan Spatz)
ProfileDr. Alan Spatz is Director of the Pathology Department at the Jewish General Hospital, and Professor of Pathology and Oncology at McGill University and holds a Canada Research Chair in Molecular Pathology. Dr. Spatz presently directs the X chromosome and Cancer research lab at the Lady Davis Institute and leads an international research group on cutaneous melanoma. He has authored more than 180 original scientific papers, reports, review articles, and books. Research Interests Recent PublicationsBiopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy. |
340-8222 ex. 5470 |
340-8102 |
C.M. Telleria, Ph.D. (University of San Luis Argentina)Email: carlos.telleria [at] mcgill.ca (Carlos Telleria) ProfileDr. Carlos Telleria is a reproductive endocrinologist whose research focuses on understanding the molecular mechanisms driving the physio-pathology of reproductive-related tissues. Dr. Telleria received his doctoral training from the National Council for Scientific and Technical Research (Conicet) of Argentina, and acquired postdoctoral expertise at the Department of Physiology, College of Medicine of the University of Illinois at Chicago. Before joining the Department of Pathology at McGill University, Dr. Telleria navigated the academic ranks at the Division of Biomedical Sciences of the Sanford School of Medicine of the University of South Dakota. During his years as an academic researcher Dr. Telleria mentored several undergraduate and graduate students, and received various awards for research and teaching excellence. Dr. Telleria is currently member of the editorial board of various peer review scientific journals, including Hormones and Cancer, Scientific Reports, Biology of Reproduction, Reproductive Biology and Endocrinology, and Cancer Growth and Metastasis. Research Interests Recent PublicationsMifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. Long-term primary culture of a clear cell ovarian carcinoma reveals an epithelial-mesenchymal cooperative interaction. |
398-5192 |
398-7446 |
Associate Professors
Name and email |
Phone |
Fax |
---|---|---|
J. Arseneau; M.D. (Laval), F.R.C.P.(C)Email: jocelyne.arseneau [at] mcgill.ca (Dr. Jocelyne Arseneau) |
934-1934 ex. 38771 | 934-8296 |
C. Bernard; M.D. (Sher.)Email: chantal.bernard [at] muhc.mcgill.ca (Dr. Chantal Bernard) |
934-1934 ex. 22220 |
412-4258 |
F. Brimo; M.D. (Syria), F.R.C.P.(C)Email: fadi.brimo [at] mcgill.ca (Dr. Fadi Brimo) ProfileClinical Expertise Research Focus Recent PublicationsRecommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA). Neoadjuvant Chemotherapy-Related Histological Changes in Radical Cystectomy: Assessment Accuracy and Prediction of Response. Fumarate Hydratase-deficient Renal Cell Carcinoma is Strongly Correlated with Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome. The atypical urothelial cell category in the Paris System: Strengthening the Achilles' heel. Changes in the expression profiles of claudins during gonocyte differentiation and in seminomas. G. Manku, A. Hueso, F. Brimo, P. Chan, P. Gonzalez-Peramato, N. Jabado, T. Gayden, M. Bourgey, Y. Riazalhosseini M. Culty. L. Florianova, B. Xu, S. Traboulsi, H. Elmansi, S. Tanguay, A. Aprikian, W. Kassouf, F. Brimo. The Molecular Taxonomy of Primary Prostate Cancer. Genitourinary tuberculosis in North America: A rare clinical entity. Cystic clear cell papillary renal cell carcinoma: is it related to multilocular clear cell cystic neoplasm of low malignant potential? Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant. BCG-related renal granulomas managed conservatively: A case series. Urine cytology: does the number of atypical urothelial cells matter? A qualitative and quantitative study of 112 cases. Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy. |
934-1934 ex. 43843 |
934-8296 |
S. Camilleri-Broët; M.D. Ph.D. (Paris)Email: sophie.camilleri-broet [at] muhc.mcgill.ca (Dr. Sophie Camilleri-Broët) ProfileDr. Sophie Camilleri-Broët received her MD degree with a specialization in Pathology and her PhD from the medical and scientific University Pierre et Marie Curie (Paris). She then completed a one year research fellowship at the Fred Hutchinson Cancer Research Center (Seattle), and spent three months at the Genome Institute of Singapore as invited scientist. Dr. Camilleri-Broëtwent went on to practice Thoracic Pathology at Hôtel Dieu Hospital in Paris, and GI Pathology at the Hôpital Européen Georges Pompidou. Selected PublicationsIntertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. |
934-1934 ex. 38774 | 934-8296 |
B. Case; B.Sc., M.D.,C.M., M.Sc. (McG.) Dipl. Occ. Hyg., F.R.C.P.(C)Email: bruce.case [at] mcgill.ca (Dr. Bruce Case) ProfileDr. Bruce Case is a pathologist and epidemiologist at McGill University in Montreal, Canada. Following his residency in pathology at McGill University he trained with Graham Gibbs and obtained the Diploma in Occupational Hygiene at McGill in 1980, and worked as a post‐doctoral fellow and instructor at the Mount Sinai School of Medicine, New York, from 1980‐83. For this work he was supported by a Fellowship in Occupational Health Research, Conseil de la Recherche en Santé du Québec . While at Mount Sinai Dr. Case performed some of the first studies on asbestos‐mediated free radical release, with the help of the Young Investigator’s Award of the American Lung Association. On his return to McGill he joined with Corbett and Alison McDonald and Patrick Sébastien in the Dust Disease Research Unit: the focus of this group was the epidemiological study of diseases related to mineral fibre exposure using lung‐retained fibre in exposure assessment. In 1986 he received the National Health Scholarship of NHRDP (Canada) for his work in the field. Research Interests Selected PublicationsMany of Dr. Case's publications are available on ResearchGate. Overreliance on a single study: there is no real evidence that applying quality criteria to exposure in asbestos epidemiology affects the estimated risk. |
934-1934 ex. 44398 |
934-8296 |
M.F. Chen; M.B., B.S. (Monash), F.R.C.P.(C)Email: moyfong.chen [at] mcgill.ca (Dr. Moy Fong Chen) |
934-1934 ex. 22353 |
934-8296 |
P. Fiset, MDCM, PhD, FRCPC (McG)Email:pierre.o.fiset [at] mail.mcgill.ca ( Dr. Pierre Fiset)
|
||
Marie-Christine Guiot; B.Sc., M.D. (Bordeaux)Email: marie.christine.guiot [at] mcgill.ca (Dr. Marie-Christine Guiot) |
398-5319 | 398-5825 |
T. Haliotis, M.D. (Greece), Ph.D. (Queen's)Email: tina.haliotis [at] mcgill.ca (Dr. Tina Haliotis) ProfileDr. Tina Haliotis is a hematopathologist with a PhD in immunology and experience in basic scientific research in the fields of molecular and cellular oncology. Selected PublicationsGastrointestinal stromal tumor with autonomic nerve differentiation and coexistent mantle cell lymphoma involving the appendix. |
340-8222 ex. 5472 |
340-8102 |
Y. Kanber; M.D. (Turkey)Email: yonca.kanber [at] muhc.mcgill.ca (Dr. Yonca Kanber) |
934-1934 ex. 62610 | 934-8296 |
J. Karamchandani; M.D. (Stanford)Email: jason.karamchandani [at] mcgill.ca (Dr. Jason Karamchandani) ProfileDr. Jason Karamchandani graduated from Harvard College and attended medical school at Stanford University School of Medicine, where he remained for his residency training in anatomic pathology. He followed up with fellowship training in surgical pathology and neuropathology. Dr. Karamchandani went on to practice neuropathology at St. Michael’s Hospital in Toronto, where he served as the director of the immunopathology laboratory. Recent PublicationsEmphysematous esophagitis associated with Sarcina organisms in a patient receiving anti-inflammatory therapy. |
398-5348 | 398-5825 |
V. Marcus, M.D., C.M.(McG), F.R.C.P.(C)Email: victoria.marcus [at] muhc.mcgill.ca (Dr. Victoria Marcus) |
934-1934 ex. 43860 |
934-8296 |
V.-H. Nguyen; M.D. (Montr.), F.R.C.P.(C)van-hung.nguyen [at] muhc.mcgill.ca (Email: Dr Van-Hung Nguyen) |
934-1934 ex. 22198 |
412-4258 |
M. Pelmus; M.D.Email: mpelmus [at] jgh.mcgill.ca (Dr. Manuela Pelmus) ProfileDr. Pelmus has received her MD and PhD degrees from the “Carol Davila” University of Medicine and Pharmacy in Bucharest, Romania. She underwent residency training in Pathology at the same institution, followed by fellowships training in Bone Pathology and in Soft Tissue Tumors at Cochin Hospital (Paris, France) and Bergonié Institute (Bordeaux, France). |
340-8222 4340 |
340-8102 |
M. Pusztaszeri; M.D.Email: marc.pusztaszeri.ccomtl [at] ssss.gouv.qc.ca (Dr. Marc Pusztaszeri) ProfileDr. Marc Pusztaszeri obtained his MD degree from University of Lausanne, Switzerland, in 2001. He then completed a six years residency program in Pathology at CHUV, Lausanne, Switzerland, including one year in radio-oncology. Shortly after finishing his residency, he practiced for 18 months in a private laboratory (Unilabs) before returning in the academic environment at Geneva University Hospitals in 2010, where he developed his current specialization of head and neck pathology, thyroid pathology, and cytopathology. In 2012, he did a visiting fellowship at the Massachusetts General Hospital in Boston, where he established a strong connection with Prof. William Faquin, director of head and neck pathology. Since October 2017, Dr. Pusztaszeri has been an Associate Professor of Pathology at the McGill University as well as a staff pathologist at the Jewish General Hospital. His clinical and research interests have focused mainly on cytopathology and surgical pathology of the thyroid gland and salivary gland tumors. He has authored or co-authored over 85 peer-reviewed publications, and has contributed to several chapters for important reference textbooks for thyroid and salivary gland cytopathology. He is recognized for his contributions for updating the Bethesda System for Reporting Thyroid Cytopathology, which plays a key role for the management of patients with thyroid nodules, and for the recent Milan System for Reporting Salivary Gland Cytopathology, an international team effort sponsored by the ASC and IAC which is expected to improve the management of patient with salivary gland lesions. He serves as an editorial board member for several important journals in the field of cytopathology and as an ad hoc peer-reviewer for many other journals. Clinical Expertise
Selected PublicationsThe Bethesda System for Reporting Thyroid Cytopathology: Proposed Modifications and Updates for the Second Edition from an International Panel Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Fine-needle aspiration of primary Langerhans cell histiocytosis of the thyroid gland, a potential mimic of papillary thyroid carcinoma. MYB immunostaining is a useful ancillary test for distinguishing adenoid cystic carcinoma from pleomorphic adenoma in fine-needle aspiration biopsy specimens. |
340-8222 ext 4197 |
340-8120 |
L. Rochon; M.D. (Sher.), F.R.C.P.(C)Email: louise.rochon [at] mcgill.ca (Dr. Louise Rochon) ProfileDr. Louise Rochon is a Senior Pathologist at the Jewish General Hospital, with expertise in Head and Neck and Thyroid Pathology. At McGill, she is Associate Professor in Pathology and Otorhinolaryngology. Recent PublicationsUltrasound-guided fine-needle aspiration of thyroid nodules: does size matter?
|
340-8222 ex. 5474 |
340-8102 |
E.A. Zorychta; Ph.D. (McG.)Email: edith.zorychta [at] mcgill.ca (Dr. E.Zorychta) |
398-7125 | 398-7446 |
Assistant Professors
Name and email |
Phone |
Fax |
---|---|---|
O. E. Ajise, M.D., F.C.A.P., F.R.C.P.(C)Email: oluyomi.ajise [at] muhc.mcgill.ca (Dr. Yomi Ajise) ProfileDr. Oluyomi (Yomi) Ajise is a Board certified in Anatomic Pathology in Canada by the Royal College of Physicians and Surgeons of Canada; and in Anatomic Pathology and Clinical Pathology in the United States by the American Board of Pathology. She is a fellow of the Royal College of Physicians and Surgeons of Canada and a fellow of the College of American Pathologists. |
934-1934 ex. 43839 |
934-8296 |
M. Alameldin; M.D., F.R.C.P.(C)Email: malameldin [at] jgh.mcgill.ca (Dr. Mona Alameldin) |
340-8222 ex. 5494 |
340-8102 |
O. Aleynikova; M.D. (Dalhousie), F.R.C.P.(C)Email: olga.aleynikova [at] mcgill.ca (Dr. Olga Aleynikova) |
340-8222 ex. 6744 |
340-8102 |
K. Bakdounes; M.D. (Syria)Email: khldoon.bakdounes [at] ssss.gouv.qc.ca (Dr. Khldoun Bakdounes) ProfileDr. Khldoun Bakdounes is the Chief pathologist at St Mary Hospital center and Assistant Professor at the department of Pathology, McGill University. He received his MD in 1994 from the Damascus University Damascus, Syria. Dr. Bakdounes pursued his training as a pathologist at State University of New York, combining this with his Masters in Public Health. Thereafter, he finished two fellowships in selective pathology and cytopathology. He was board certified as an anatomical and clinical pathologist in 2006 and cytopathology in 2008. Dr. Bakdounes is a fellow of the Royal College of Physicians of Canada since 2007 and is a Licentiate of the Medical Council of Canada. |
345-3511 ex. 3732 |
734-2743 |
M. Blumenkrantz; M.D. (McG)Email: miriam.blumenkrantz [at] muhc.mcgill.ca (Dr. M. Blumenkrantz) |
412-2610 | 412-4258 |
J. Burnier Ph. D. (McGill)Julia.burnier [at] mcgill.ca (Email: Dr. Julia Burnier)
ProfileDr. Burnier completed a PhD in molecular and cell biology at McGill University (Experimental Medicine). The focus of her PhD was the molecular mechanisms underlying invasion and metastasis. Dr. Burnier went on to pursue related post-doctoral training at McGill and at the Centre for Genomic Regulation (Barcelona, Spain). She then studied cancer genomics in clinical trials at the Princess Margaret Hospital (Toronto). Research Interests and Areas of expertiseUnderstanding the dynamic molecular changes that occur during tumor progression and metastasis, with a focus on ocular tumors. Identifying tumor markers that can be used to track disease through liquid biopsies. Selected PublicationsEyelid Mycetoma Masquerading as Sebaceous Carcinoma. Analysis of HSP90 Expression Is Valuable in the Differential Diagnosis of Ocular Surface Squamous Lesions Pericyte Status in Routinely Discarded Vitrectomy Samples May Be an Early Marker of Diabetic Retinopathy. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. |
||
D. Caglar; M.D. (Turkey)Email: derin.caglar [at] muhc.mcgill.ca (Dr. Derin Caglar) |
934-1934 ex. 43837 |
934-8296 |
|
345-3511 ex. 3690 |
734-2743 |
G. Evaristo; HBSc (McG.), MD (Montr.), FRCP(C)Email: gertruda.evaristo [at] mcgill.ca (Dr. Greta Evaristo) ProfileDr. Greta Evaristo is a Gastrointestinal and Liver pathologist, double board certified by the Royal College of Physicians & Surgeons of Canada and the American Board of Pathology. She received her MD degree at the University of Montreal after obtaining a BSc with honours in Microbiology & Immunology from McGill University. After returning to McGill to complete her anatomical pathology residency, Dr. Evaristo went on to pursue a Gastrointestinal & Hepatic pathology fellowship at the University of Chicago under the direction of Dr. John Hart. Her main academic interests include hepatobiliary and gastroesophageal neoplasms, as well as medical liver pathology. Dr. Evaristo likewise has a particular interest in medical education and serves on several committees, including USCAP (Education Committee, CME Subcommittee) and AASLD (Liver Fellow Network, Pathology Pearls). Recent PublicationsORCID ID: 0000-0002-6750-9026 or click on |
||
A. Florea; M.D. (Romania)Email: anca.florea [at] mcgill.ca (Dr. Anca Florea) ProfileDr.Anca Florea received her MD degree from the “Iuliu Hatieganu” University of Medicine and Pharmacy in Cluj-Napoca, Romania. She underwent residency training in Anatomic and Clinical Pathology at the University of Pittsburgh Medical Center in Pittsburgh, Pennsylvania, USA, followed by a one year fellowship training in Breast and Gynecologic Pathology at the same institution. Since July 2011, Dr. Florea has been an Assistant Professor of Pathology at the McGill University as well as staff pathologist at the Jewish General Hospital in Montreal, Canada. |
340-8222 ex. 5480 |
340-8102 |
Dr Livia Florianova, MD, MSc, FRCPCEmail: livia.florianova [at] mail.mcgill.ca (Dr. Florianova) ProfileDr Livia Florianova, MD, MSc, FRCPC is thrilled to have joined the Department of Pathology at McGill University as an Assistant Professor at the Jewish General Hospital in July 2018. She completed her medical studies at Université Laval in Quebec City (2012), where she also obtained a Master's degree in Experimental Medicine (2011). Following her residency at McGill University (2012-2017), she trained one year at the University of Toronto as a Surgical Pathology fellow at St. Michael's Hospital with independent sign-out and staff responsibilities. During that year, she also completed electives at the Toronto General Hospital and the Sunnybrook Health Sciences Centre. Livia's main areas of interest are breast, head & neck and thyroid pathology. She aims to enrich her understanding of these topics though clinical research projects including collaborative research studies. She also looks forward to actively participate in resident education. In her spare time, Livia catches up on art history, music, plays hockey, swims and explores the beauties of the natural world. |
340-8222 ex. 24161 |
340-8102 |
L. Fu, M.D.,C.M. (McG)Email: lili.fu [at] muhc.mcgill.ca (Dr. Lili Fu) |
934-1934 ex. 43835 |
934-8296 |
A. Gologan; M.D. (Romania)Email: adrian.gologan [at] mcgill.ca (Dr. A. Gologan) |
340-8222 ex. 3767 |
340-8102 |
A. Gregorieff B.Sc. ( Université Laval), M.Sc. (McGill University), Ph.D. (Universiteit Utrecht)Email: Dr.alex.gregorieff [at] mcgill.ca ( )alex.gregorieff [at] mcgill.ca (A Gregorieff) ProfileMy current research interests stem from my doctoral thesis in the lab of Dr. Hans Clevers in the Netherlands. During this time, I studied the Wnt/Tcf pathway and its role in driving intestinal development and homeostasis. Next, I moved to Toronto to pursue my postdoctoral training in the lab of Dr. Jeff Wrana at the Lunenfeld-Tanenbaum Research Institute. Here, I became interested in studying the role of the Hippo signaling effector, Yap, in intestinal stem cells during regeneration and cancer initiation. In 2017, I was appointed assistant professor in the department of pathology at McGill University. My future research goals will be to study the role of the Hippo pathway in stromal cells during gut homeostasis and tumorigenesis. Secondly, I am also interested in dissecting the signals underlying cellular plasticity of adult stem cells. To achieve these goals, I am currently developing a broad range of genetic tools including Cre-lox based mice for gene targeting and lineage tracing experiments, as well as ex vivo organoid culture systems. Recent PublicationsHippo signalling in intestinal regeneration and cancer A critical role for NF2 and the Hippo pathway in branching morphogenesis YAP and TAZ control peripheral myelination and the expression of laminin receptors in Schwann cells Seeing is believing: Wnt3 localization in the gut epithelium Multiple roles for the hippo effector yap in gut regeneration and cancer initiation YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer |
934-1934 |
|
S.Jung; M.D. (Korea)Email: sung-mi.jung [at] muhc.mcgill.ca (Dr. Sungmi Jung) |
934-1934 ex. 43842 |
934-8296 |
Dr. Baharak Khadang (MD, PhD, FRCPC)Email: Dr. baharak.khadang [at] mcgill.ca (Baharak Khadang)
|
345-3511, ext: 3182 |
|
J. Lavoie; M.D., Ph.D. (Laval)Email: jlavoie [at] muihc.mcgill.ca (Dr. )jlavoie [at] muihc.mcgill.ca (Josée)jlavoie [at] muihc.mcgill.ca ( Lavoie) Recent PublicationsVGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer. |
934-1934 ex. 23544 |
412-3544 |
H.R.Lopez-Valle;M.D. (Mexico)Email: hilda-ruth.lopez-valle [at] ssss.gouv.qc.ca (Dr. Hilda Ruth Lopez-Valle) |
345-3511 ex. 3734 |
734-2743 |
A.T. Marcus; B.Sc., M.D., C.M. (McG), F.R.C.P.(C)Email: alexander.marcus [at] ssss.gouv.qc.ca (Dr. Alexander T. Marcus) |
345-3511 ex. 3456 |
734-2743 |
Dr. Lara RicherEmail: Dr. Lara Richer |
||
Teddy Sutardji Nagaria,Email: teddy.nagaria [at] mcgill.ca (Dr. Teddy Nagaria,) |
||
Dr. Basile Tessier-CloutierEmail: basile.tessiercloutier [at] mcgill.ca (Dr. Basile Tessier-Cloutier ) |
||
Tuyet Nhung Ton Nu MD, FRCPCEmail: tuyet.tonnu [at] mcgill.ca (Dr. Ton Nu) |
934-1934 Ext. 143786 |
934-8437 |
A. Omeroglu, M.D. (Turkey)Email: atilla.omeroglu [at] muhc.mcgill.ca (Dr. Atilla Omeroglu) |
934-1934 ex. 62266 | 934-8296 |
F. Razaghi, M.D. (Iran)Email: farshid.razaghi.chsm [at] ssss.gouv.qc.ca (Dr. Farshid Razaghi) ProfileDr. Razaghi received his MD from the “Beheshti” University of Medical science in Tehran, Iran. He underwent residency training in Pathology at McGill University, followed by fellowship training in Cytology at Dartmouth-Hitchcock Medical Center in New Hampshire, USA. |
345 3511 ex. 3731 | 734 2743 |
Margaret RedpathEmail: margaret.redpath [at] mcgill.ca (Dr. Margaret Redpath ) ProfileDr. Redpath is an assistant professor in the Department of Pathology at McGill University and a practicing dermatopathologist at the Jewish General Hospital. She completed both her Bachelor of Science in Physiology and her medical degree at McGill University. During her residency training in Anatomical Pathology, Dr. Redpath began her Master of Science through the Royal College’s Clinician Investigator Program. Her research involves examining the role of tumor suppressor genes on the X chromosome in melanoma to better understand the significantly increased incidence and mortality of melanoma in men compared to women. Dr. Redpath recently received her PhD in Pathology from McGill University and completed her fellowship training in dermatopathology at Toronto General Hospital. Clinical Expertise and Research InterestsContent B Selected PublicationsContent C |
||
J. St. Cyr; M.D.,C.M. (McG.), F.R.C.P.(C)Email: julie.st-cyr [at] ssss.gouv.qc.ca (Dr. Julie St-Cyr) |
345-3511 ex. 3076 |
734-2743 |
H. Wang; M.D. (China)Email: hangjunwang [at] jgh.mcgill.ca (Dr. Hangjun Wang) |
340-8222 ex. 5470 |
340-8102 |
Part-Time Associate Professors
A.K. Watters; B.Sc., M.D., C.M. (McG), F.R.C.P.(C)Email: kevin.watters [at] muhc.mcgill.ca (Dr. A.K. Watters) |
934-1934 ex. 43840 |
934-8296 |
Part-Time Assistant Professors
B. Ahmadi Kaliji, M.D., FRCPCEmail: babak.ahmadikaliji [at] mcgill.ca (Dr. Babak Ahmadi Kaliji) ProfileDr Ahmadi Kaliji received his MD degree from the Tehran university of medical sciences in Tehran, Iran. He underwent residency training in Anatomic Pathology at the University of Sherbrooke and McGill university. Dr Ahmadi Kaliji is a fellow of royal college of physicians and surgeons of Canada and a staff pathologist at the Lakeshore general hospital. Clinical Expertise and Research InterestsGenitourinary pathology, Breast Pathology, Hematopathology, Cytology and Kidney tumors Selected Publications |
(514) 630-2225 Ext. 5528 |
|
S. Sandhu;M.B.B.S. (India)Email: sangeeta.sandhu [at] ssss.gouv.qc.ca (Dr. Sangeeta Sandhu)
ProfileDr. Sangeeta Sandhu earned her Medical Degree (M.B.B.S.) from North Bengal Medical College, Sushrutanagar, India in 1990. She obtained a Prosectorship in Biochemistry and topped her final MBBS in Surgery to prove that she had a keen analytic mind and the cutting edge. After completing her internship in a rural based setting she went on to do an obligatory year of residency in Obstetrics and Gynecology at the Post Graduate Institute, Kolkata, West Bengal. As she started her second year of residency in Radiation Oncology, she was drawn towards the diagnostic aspect of disease progression and felt she could better serve humanity by placing herself at the critical junction between prevention and cure. She completed her post graduate training and became board certified in Combined Anatomic and Clinical Pathology from St. Luke’s-Roosevelt Hospital Center, Columbia University, New York city. This was followed by a fellowship in Surgical Oncologic Pathology, at the University of Illinois, Chicago and a second fellowship in Hematopathology at the Albert Einstein College of Medicine, New York. She trained in Molecular Diagnostics at the National Institute of Health, Bethesda with Drs. Elaine Jaffe and Mark Raffeld.
|
345-3511 ex. 3690 |
|
Yu Jing Wang, MDCM, FRCP(C)Email: yujing.wang [at] mail.mcgill.ca (Yu Jing Wang,) ProfileAnatomopathologiste |
||
Pylyp zolotarovEmail: pylyp.zolotarov [at] mcgill.ca (Dr. Pylyp Zolotarov) ProfileC |
Associate Members
Name and email |
Phone |
Fax |
---|---|---|
B. S. Abdulkarim; M.D., Ph.D., (Paris) F.R.C.P.(C)Email: bassam.abdulkarim [at] mcgill.ca (Dr. Bassam Abdulkarim) ProfileDr. Bassam Abdulkarim is an Associate Professor in the Department of Oncology (Director, Division of Radiation Oncology, since April, 2011) and principle investigator at the Research Institute of the MUHC. Dr. Abdulkarim joined the Department of Pathology as an associate member in 2013. Recent PublicationsYB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells. |
934-1934 ex. 43594 |
934-8392 |
C.J. Baglole; Ph.D. (University of Calgary)Email: carolyn.baglole [at] mcgill.ca (Dr. Carolyn Baglole) ProfileDr. Baglole received her BSc and MSc from the University of Prince Edward Island, and her PhD from the University of Calgary. She then did postdoctoral research and subsequently joined the academic staff at the University of Rochester, before returning to Canada where she is currently an Assistant Professor in the Department of Medicine and an Associate Member in the Department of Pathology at McGill. Research Interests: The research in her laboratory is aimed at identifying novel intracellular and molecular pathways that control the pathogenesis of chronic lung diseases associated with environmental exposures, particularly cigarette smoke. Her main focus is understanding how cigarette smoke-induced inflammation and cell death (apoptosis) are regulated. Chronic and persistent inflammation and the death of lung cells are involved in the etiology of lung diseases such as chronic obstructive pulmonary disease (COPD), which is almost always caused by cigarette smoke (>90% of cases). There is no cure for individuals afflicted with COPD and there are no effective therapies that can reduce disease progression. This is due, in part, to a lack of novel intracellular targets for the development of pharmacological therapies. In this regard, her lab was the first to publish that the mere presence of a cellular receptor called the aryl hydrocarbon receptor (AhR) attenuates lung inflammation caused by cigarette smoke. This was a novel finding, as the normal physiological function of this receptor, which is best known for its ability to respond to synthetic toxicants, had not previously been described. Beyond its regulation of inflammation in the lung caused by cigarette smoke, they also investigate the role of the AhR in attenuating apoptosis, a feature that is characteristic of lung tissue destruction in COPD. Using genetic, molecular and biochemical approaches, together with in vitro and in vivo models of smoke exposure, her research is focused on establishing that the AhR is a novel and important regulator of apoptosis and understanding in vivo, and the role of the AhR in preventing morphological features of emphysema in the lung. Recent PublicationsThe NF-κB Family Member RelB Attenuates Cigarette Smoke Extract-induced Apoptosis in Lung Fibroblasts via Transcriptional Regulation of the Aryl Hydrocarbon Receptor Inhaled Pollutants: The Molecular Scene behind Respiratory and Systemic Diseases Associated with Ultrafine Particulate Matter Aryl hydrocarbon receptor (AhR)-dependent regulation of pulmonary miRNA by chronic cigarette smoke exposure Monocyte-derived fibrocytes induce an inflammatory phenotype in airway smooth muscle cells. |
934-1934 ex. 76109 |
398-7483 |
N. Braverman; MD, M.Sc. (Tulane University; Sarah Lawrence College )Email: nancy.braverman [at] mcgill.ca (Dr。 Nancy Braverman) ProfileDr. Braverman received her BSc from Cornell University and her Master in Human Genetics from Sarah Lawrence College。 She then received her M.D. from Tulane University, completed residency training in Pediatrics at Yale-New Haven hospital, followed by a Fellowship in Clinical and Biochemical Genetics at Johns Hopkins. She then joined McKusick-Nathan's Institute of Genetic Medicine as an Assistant Professor at Johns Hopkins University, and subsequently joined McGill where she is now an Associate Professor with tenure in the Department of Medicine and an Associate Member in the Department of Pathology at McGill. Research Interests: The research in her laboratory is focused on a group of inherited disorders caused by defects in the genes responsible for the proper function of peroxisomes, important components of cells that help to metabolize lipids, or fatty acids. Peroxisomal disorders can involve either the assembly of the peroxisome itself (as in peroxisome biogenesis disorders), or specific enzymes located in the peroxisome. All of these conditions feature the loss of enzymes required by the body to metabolize important lipids. The consequences are a progressive disease of the nervous system, eye, hearing, bone, liver, kidney and adrenal glands. Her laboratory engineers mouse models of the disorders to investigate how these enzyme defects cause disease. To provide patients and their families with better prognostic information and care, the laboratory has established a patient registry documenting variations in disease outcome and is identifying drugs and therapies that can improve outcomes. The clinical trial of one drug is underway. Recent Publications |
934-1934 ex. 23404 |
|
Sonia Cellot , M.D. , Ph.D. (Université de Montréal) ProfileDr. Sonia Cellot is an Assistant Professor in the Department of Pediatrics at Université de Montréal and an investigator in the Viral and Immune Disorders and Cancers axis at CHU Sainte-Justine Research Center. She is a clinician-scientist with a BSc in Biochemistry from McGill, an MD from the Université de Montréal, Royal College certification in both Pediatrics and Hematology, and a PhD in Molecular Biology from the Université de Montréal. She has been a pediatric hematologist in the Hematology-Oncology Division of CHU Sainte-Justine since 2009, where she is responsible for the pediatric acute myeloid leukemia (AML) program and is the Assistant Director of the Immune disorders and Cancer research axis at CHU- Sainte-Justine . Clinical duties encompass direct patient care, mainly in the hematopoietic stem cell (HSC) transplantation unit, and diagnostic test development as medical advisor in the molecular biology laboratory. Since 2010, she has been the co-investigator of the pediatric branch of the Quebec Leukemia Cell Bank, in collaboration with Dr Josée Hébert, hematologist at Hôpital Maisonneuve-Rosemont, with the mandate to collect highly annotated pediatric AML and infant leukemia samples to support and promote research projects. Her research focus is on hematopoietic stem cell (HSC) biology and the development of human synthetic leukemia models to identify therapeutic vulnerabilities in high fatality pediatric leukemia. Long-lived HSC sustain the constant production of all mature cell lineages in the blood system, and constitute the critical cellular component of transplantation procedures performed in oncology for high risk malignancies, including leukemia. Nonetheless, factors that dictate HSC fate remain poorly defined, and their isolation and ex vivo culture remain challenging, limiting their clinical applications. The main focus of the laboratory is to study the role of chromatin methylation in human HSC biology. Accessibility of the transcriptional machinery to the genetic code is mediated through the concerted actions of chromatin modifying enzymes. The Mll (Mixed Lineage Leukemia) gene, encoding for a histone methyltransferase (of lysine 4 on histone 3, or H3K4) is involved in normal HSC maintenance and mutated in >70% of infant leukemia cases. Once thought to be irreversible, histone methylation is now regarded as a highly dynamic process, since the identification of the histone demethylase LSD1 (KDM1A) in 2004. Previous work identified that JARID1B (KDM5B), an eraser of the H3K4 epigenetic mark, regulates the expression of stemness associated genes, and its knockdown leads to HSC expansion in culture. The implication of histone demethylases (HDM) in HSC biology and cancer development is being unraveled, and under active pharmacological investigation.
Recent Publications |
514-345-4870 | 514-345-4881 |
P.J. Chauvin; M.Sc. (W.Ont.), D.D.S. (McG.)Email: peter.chauvin [at] muhc.mcgill.ca (Dr. Peter J. Chauvin) |
934-1934 ex. 43844 |
934-8296 |
M. Divangahi; Ph.D. (McG)Email: maziar.divangahi [at] mcgill.ca (Dr. Maziar Divangahi) ProfileDr. Maziar Divangahi completed his PhD in the Department of Medicine at McGill University in 2005. He went to pursue three fellowships in Molecular Immunology and Infectious Diseases at McMaster University, McGill and Harvard University before being appointed at McGill as an Assistant Professor in the departments of Medicine and Microbiology & Immunology. He joined the Department of Pathology as an associate member in 2012. PublicationsAnnexin1 regulates DC efferocytosis and cross-presentation during Mycobacterium tuberculosis infection. |
934-1934 ex.76431 |
398-7483 |
Nada Jabado, MD, PhDnada.jabado [at] mcgill.ca (E-mail: Dr. Nada Jabado) ProfileDr. Nada Jabado is a Professor of Pediatrics and staff physician in the Department of Hematology and Oncology at the Montreal Children’s Hospital. She completed her residency in pediatrics with a specialization in hemato-oncology, obtained a PhD in Immunology in Paris and followed that by a postdoctoral fellowship in biochemistry at McGill. She began her career as an independent investigator at The Research Institute of the McGill University Health Centre in 2003, pioneering a research program in pediatric brain tumours which is now unparalleled. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumours. More importantly, they identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1) at amino acid positions K27 (Lysine to Methionine, K27M) and G34 (Glycine to Valine or Arginine, G34V/R). A true clinician-scientist, Dr. Jabado leads a lab comprised of 6 postdoctoral and clinical fellows, 6 graduate students and 5 research assistants/associates. Her ground-breaking work has created a paradigm shift in cancer with the identification of histone mutations in human disease for the first time. This finding has revolutionized the field, as the epigenome was a previously unsuspected hallmark of oncogenesis, thus linking development and what we now know are epigenetic-driven cancers. This work and other publications in the subject are considered landmark papers (over 3000 citations since 2012).
Research Interests and selected publicationsAs an independent Principal Investigator, Dr. Jabado's has embarked on elucidating genetic signatures of pediatric astrocytomas and examining how they compare to adults. These are deadly brain tumours that originate in brain and include glioblastomas (GBM, the highest grade of astrocytomas), which are one of the deadliest cancers in humans. Her group uncovered that pediatric high-grade astrocytomas (HGA) are molecularly and genetically distinct from adult tumors. They also identified a new molecular mechanism driving pediatric HGA, namely recurrent somatic driver mutations in the tail of histone 3 variants (H3.3 and H3.1). These mutations lead to amino acid substitutions at key residues and are tightly correlated with a distinct global DNA methylation pattern, neuroanatomical locations and age specificities. Their findings position them as leaders in the field of HGA, at the forefront of significant breakthroughs for this deadly brain tumor. Crucial impediments to progress are the lack of reliable in vitro and in vivo models for these “oncohistones” and understanding their effects in driving tumors and therapeutic resistance. they aim to identify events affected downstream of each mutation, and validate targets in their new models to better advise the use of experimental or pipeline drug(s) or drug combinations that could be rapidly translated into clinical trials. Ultimately, based on their findings, patients could be stratified based on their genetic/molecular signature, and assigned to a beneficial therapeutic strategy, bringing needed effective interventions in this devastating cancer. Additionally, they established a TCGA-like initiative by creating the International CHildhood Astrocytoma INtegrated Genomic and Epigenomic (ICHANGE) Consortium. This is a unique set of resources which enables the scientific world to investigate astrocytomas in children. It includes databases and access to technology as well as international collaborations from 15 participating countries, including ~1500 annotated glioma tissue samples representative of all grades and ages. Diffuse intrinsic pontine gliomas -current management and new biologic insights. Is there a glimmer of hope? Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape.
|
||
Jun-Li Liu, PhD. (McGill University)Email: un-li.liu [at] mcgill.ca (Dr. J-L Liu) Biographical SketchRecent PublicationsClick on to see Dr. JL-Liu's current publications list |
934-1934 ex. 35059 |
|
Shuk On Annie LeungEmail: annie.leung [at] mcgill.ca (Dr. A Leung) ProfileDr. Annie Leung is a gynecologic oncologist at the McGill University Health Center in Montreal, Quebec, Canada. She is affiliated with the Departments of Obstetrics and Gynecology, Oncology, and Pathology. In her clinical practice, she treats patients with gynecologic malignancy throughout the cancer journey offering surgery, chemotherapy, targeted therapies, and palliative care. For cervical pre-cancer, she also provides care in colposcopy clinic for patients with abnormal paps and positive HPV results. Recent Publications
|
||
P. Metrakos; M.D. C.M. (McGill University)Email: peter.metrakos [at] muhc.mcgill.ca (Dr. Peter Metrakos) |
934-1934 ex. 31600 |
843 1503 |
M. Park; Ph.D. (Glasgow University, Scotland)Email: morag.park [at] mcgill.ca (Dr. Morag Park) ProfileDr. Morag Park is a James McGill Professor in the Departments of Biochemistry, Medicine and Oncology at McGill University, where she holds the Diane and Sal Guerrera Chair in Cancer Genetics. She is also the current Scientific Director of the CIHR Institute of Cancer Research. Dr. Park has published over 100 papers in peer-reviewed journals. Her work has been recognized with numerous awards including becoming a Fellow of the Royal Society of Canada. Recent PublicationsDeficiency of the chromatin regulator Brpf1 causes abnormal brain development. |
398-5749 | 398-6769 |
Sabah N.A. Hussain, M.D. Ph.D. Critical Care and Respiratory DivisionsEmail: sabah.hussain [at] muhc.mcgill.ca (Dr. sabah Hussain) ProfileDr. Sabah Noori Abdul Hussain is a James McGill Professor in the Department of Medicine ,( Critical Care and Respiratory Divisions appointed since July 1st, 2005); Medical Director at Pulmonary Function Laboratories since july 1999 and the Research Director at Meakins-Christie Labs of the MUHC since july 1991. Dr. Hussain joined the Department of Pathology as an associate member in 2017. Research Interests and selected publicationsDr. Hussain is currently involved in three main areas of research. First, his laboratory is currently investigating molecular signaling pathways and mechanisms of action of angiogenesis factors in general and angiopoietins and Tie-2 receptors in particular. Current project include identification of transcription factor networks downstream from Tie-2 receptors both in endothelial cells and in cultured skeletal muscle satellite cells. In addition, his laboratory is exploring the biological functions of both angiopoietin-1 and angiopoietin-2 in regulating cytokine cascade and tissue injury in various models of inflammation including severe sepsis and acute lung injury. To achieve the objective in this area of research his laboratory has developed transgenic animal models to over-express angiopoietins selectively in the vasculature. His second area of research is the biological roles of angiopoietins in skeletal muscle regeneration with particular emphasis on ventilatory muscle function. In this regard, we are investigating the effectiveness of gene therapy in which angiopoietins are delivered in vivo in various models of skeletal muscle injury and regeneration including cardiotoxin necrosis model and mdx model of Duchenne Muscular Dystrophy. His third area of research interest is molecular mechanisms involved in skeletal muscle atrophy in general and regulation of autophagy and proteosomal pathways in particular. Current research project include assessing the contribution of autophagic pathway to skeletal muscle protein degradation in human diaphragm during mechanical ventilation. Fibulin-5 Regulates Angiopoietin-1/Tie-2 Receptor Signaling in Endothelial Cells Prolonged controlled mechanical ventilation in humans triggers myofibrillar contractile dysfunction and myofilament protein loss in the diaphragm Contribution of the Mitochondria to Locomotor Muscle Dysfunction in Patients With COPD Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p Angiopoietin-1 enhances skeletal muscle regeneration in mice Reactive oxygen species regulation of autophagy in skeletal muscles Regulation of angiopoietin-1/Tie-2 receptor signaling in endothelial cells by dual-specificity phosphatases 1, 4, and 5, Autophagic flux and oxidative capacity of skeletal muscles during acute starvation Angiogenesis-related factors in skeletal muscles of COPD patients: roles of angiopoietin-2 Muscle cell derived angiopoietin-1 contributes to both myogenesis and angiogenesis in the ischemic environment. Mechanisms of Chronic Muscle Wasting and Dysfunction after an Intensive Care Unit Stay. A Pilot Study |
9341934 Ext. |
Fax:933-3962 |
Wassim Kassouf, MD, CM, FRCSCemail: wassim.kassouf [at] muhc.mcgill.ca (Dr. Wassim Kassouf)
ProfileAfter medical school and residency at McGill University, Dr Wassim Kassouf completed a urologic oncology fellowship at M. D. Anderson Cancer Center in Houston, Texas. He then arrived on faculty in August 2006 at the McGill University Health Center, Montreal, Canada. He is a Professor in the Division of Urology and Vice-Chair, academic affairs, of the Department of Surgery at McGill University. Dr. Kassouf’s clinical practice focuses on bladder, prostate, and renal cancer. Research Interests and selected publicationsHis clinical and translational research focuses on the biology and therapy of bladder cancer. His translational research over the recent years have been primarily on biomarkers and radiosensitization in bladder cancer. Phase I clinical trial of everolimus combined with trimodality therapy in patients with invasive bladder cancer Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study. |
934-8246 |
934-8297 |
Goffredo Orazio Rinaldo Arena, MD, Chir. Vasc. (Ita), FRCS(C),Email: goffredoarena [at] gmail.com (Dr. Goffredo Orazio Rinaldo Arena, MD) ProfileDr. Goffredo Arena graduated in Italy at the University of Catania in 1997. He then moved to England where he started his training in General and Vascular Surgery at the Royal Free Hospital in London. In 2003 he transferred to McMaster University in Hamilton to continue his training in General and Vascular Surgery. In 2006 he gained the Vascular Surgery fellowship Certificate in Italy and in 2007 he obtained his General Surgery Specialist Certificate in Canada and he became a fellow of the Royal College of Surgeons. In 2007 he relocated to Montreal and he completed back to back a fellowship in Minimally Invasive Surgery and a fellowship in HPB and multi-organ transplantation at McGill University. Research Interests and selected publicationsHis main research interest focus on horizontal transfer of malignant traits and he has become worldwide one of the main advocates of the genometastatic hypothesis. He has patented a novel blood test called MATERD for cancer screening and metastatic recurrence prediction. Recently he published on the reprogramming effect of human embryonic stem cells’ exosomes on cancer cells. Transfer of malignant traits as opposed to migration of cells: A novel concept to explain metastatic disease. Reprogramming Malignant Cancer Cells toward a Benign Phenotype following Exposure to Human Embryonic Stem Cell Microenvironment. Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients. Kommerell's diverticulum and aneurismal right sided aortic arch: a case report and review of the literature. Ruptured mycotic thoracoabdominal aortic aneurysms: Three case reports and a systematic review. Cerebrospinal fluid drainage to prevent paraplegia during thoracic and thoracoabdominal aortic aneurysm surgery: A systematic review and a meta-analysis. The retrojugular approach to carotid endarterectomy- A safer technique? Laparoscopic versus open resection for colorectal cancer: a meta-analysis of oncologic outcomes. Laparoscopic vs. open resection for colorectal cancer: A meta-analysis of oncologic outcomes Staged hepatectomy for bilobar colorectal hepatic metastases
|
483 5101 |
482-4342
|
|
||
Dr. Joanna Przybyl Ph.D (KU Leuven)Email: joanna.przybyl [at] mcgill.ca (Dr. Joanna Przybyl ) ProfileDr. Joanna Przybyl received a joint Ph.D. degree in biomedical sciences from KU Leuven, Belgium and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. Her doctoral studies focused on identifying new prognostic and predictive markers for soft tissue sarcoma. She then joined the laboratory of Dr. Matt van de Rijn in the Department of Pathology at Stanford University, where she completed her postdoctoral training in computational biology. During her postdoctoral studies, Dr. Przybyl demonstrated potential clinical utility of ctDNA monitoring in patients with leiomyosarcoma and leiomyoma, discovered activation and prognostic role of hexosamine biosynthesis pathway in leiomyosarcoma, and identified macrophage infiltration in undifferentiated uterine sarcomas. In 2021, Dr. Przybyl joined the Department of Surgery of the McGill University as an Assistant Professor, and the Cancer Research Program of the Research Institute of the McGill University Health Centre (RI-MUHC) as a Junior Scientist. Dr. Przybyl is also an Associate Member in the Department of Pathology of the McGill University. Research Interests and Recent publicationsThe research projects in the laboratory of Dr. Przybyl are focused on: 1) development of liquid biopsy (circulating tumor DNA) assays for patients with soft tissue tumors, 2) metabolic reprogramming in selected types of soft tissue tumors, and 3) multi-omic profiling of soft tissue tumors to identify new diagnostic markers and therapeutic targets in these tumors.Content B |